Om

Veraxa Biotech Holding AG is an oncology-focused biotechnology company that operates Veraxa Biotech AG, a clinical-stage biopharmaceutical business dedicated to antibody-based cancer therapies. The group concentrates on developing novel drug platforms that use engineered antibodies to deliver targeted treatment to solid and hematologic tumors, with a particular emphasis on antibody-drug conjugates and T cell engagers. Central to its approach is the proprietary BiTAC concept, which enables dual-targeting mechanisms designed to improve precision and reduce off‑target effects in cancer therapy. Veraxa Biotech Holding AG leverages advanced microfluidics and genetic code expansion technologies to design, screen, and optimize these next‑generation therapeutics. Headquartered in Zurich, Switzerland, with operations centered around its R&D hub in Heidelberg, Germany, the company plays a specialized role in the global biopharmaceutical market by supplying innovative platforms and clinical candidates to address unmet needs in oncology.

Markedsdata leveret af TwelveData og Morningstar

Aktiemarkedet kan gå både op og ned. Selvom investeringer i aktier historisk set har givet investorer et positivt afkast på langt sigt, er der ingen garanti for fremtidige afkast. Der er derfor en risiko for, at du ikke får de investerede penge tilbage.

INVESTER I VERAXA BIOTECH HOLDING MED ENDAVU: Køb Veraxa Biotech Holding ($VRXA) aktier gennem Endavu’s investeringsplatform. Hos Endavu kan du købe og sælge aktier i Veraxa Biotech Holding, og handle med aktier, fraktionaler, ETF'er og andre finansielle instrumenter. Endavu tilbyder handel uden kurtage på amerikanske aktier. Endavu tilbyder lav kurtage på tværs af aktier. Handl med over 30.000 forskellige aktier og udenfor markedsåbningstider.